
Quarterly report 2022-Q2
added 08-10-2022
Liminal BioSciences EBITDA 2011-2026 | LMNL
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Liminal BioSciences
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | -85.6 M | -213 M | -226 M | -123 M | -109 M | -57.3 M | -15.1 M | -16.3 M | 2 M | -930 K |
All numbers in CAD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2 M | -226 M | -84.4 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M | ||
|
Aligos Therapeutics
ALGS
|
-87.1 M | $ 8.64 | 8.07 % | $ 85.4 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-17.3 M | $ 3.66 | -1.48 % | $ 8.81 B | ||
|
I-Mab
IMAB
|
13.8 M | - | - | $ 866 M | ||
|
AlloVir
ALVR
|
-46.1 M | - | 4.14 % | $ 49.1 M | ||
|
Applied Molecular Transport
AMTI
|
-124 M | - | - | $ 10.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
3.11 B | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
31.8 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M | ||
|
Applied Therapeutics
APLT
|
-64.5 M | - | - | $ 8.42 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
172 M | $ 21.36 | 4.86 % | $ 998 M | ||
|
Acorda Therapeutics
ACOR
|
-233 M | - | -24.86 % | $ 820 K | ||
|
Институт стволовых клеток человека
ISKJ
|
220 M | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
-136 M | - | - | $ 86.2 M | ||
|
Advaxis
ADXS
|
-35.9 M | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
-23.9 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-242 M | - | - | $ 1.01 B | ||
|
Akebia Therapeutics
AKBA
|
24.8 M | $ 1.47 | 5.0 % | $ 378 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-16.2 M | - | - | $ 26.5 M | ||
|
Allakos
ALLK
|
-190 M | - | - | $ 28.6 M | ||
|
Aptinyx
APTX
|
-62.4 M | - | -39.0 % | $ 4.57 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-9.93 M | $ 2.92 | - | $ 4.81 M | ||
|
Aquestive Therapeutics
AQST
|
-70.5 M | $ 4.19 | 2.7 % | $ 448 M | ||
|
Aravive
ARAV
|
-70 M | - | -13.39 % | $ 1.45 M | ||
|
Arcutis Biotherapeutics
ARQT
|
-11.5 M | $ 24.12 | -0.37 % | $ 3.07 B | ||
|
AIkido Pharma
AIKI
|
-55.6 M | - | 1.93 % | $ 17.4 M | ||
|
Celldex Therapeutics
CLDX
|
-284 M | $ 32.59 | 1.09 % | $ 2.16 B | ||
|
Autolus Therapeutics plc
AUTL
|
-262 M | $ 1.47 | -1.34 % | $ 391 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Cidara Therapeutics
CDTX
|
-176 M | - | - | $ 1.41 B | ||
|
AVROBIO
AVRO
|
10.8 M | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-37.3 M | - | - | $ 7.46 M | ||
|
AstraZeneca PLC
AZN
|
1.06 B | - | - | $ 96.9 B | ||
|
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | ||
|
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
-9.75 M | - | -2.5 % | $ 5.88 M | ||
|
BeiGene, Ltd.
BGNE
|
589 M | - | 0.49 % | $ 251 B | ||
|
Akouos
AKUS
|
-84.3 M | - | 0.23 % | $ 488 M | ||
|
Akari Therapeutics, Plc
AKTX
|
-21.6 M | $ 4.25 | 8.35 % | $ 286 B | ||
|
Allena Pharmaceuticals
ALNA
|
-47.3 M | - | 3.16 % | $ 1.9 M | ||
|
Esperion Therapeutics
ESPR
|
60.4 M | $ 2.22 | 2.3 % | $ 461 M | ||
|
Evogene Ltd.
EVGN
|
-31 M | $ 0.82 | 1.13 % | $ 27.9 M | ||
|
Baudax Bio
BXRX
|
-56.6 M | - | 0.59 % | $ 63 K | ||
|
Cabaletta Bio
CABA
|
-171 M | $ 3.2 | 2.24 % | $ 322 M | ||
|
Alpine Immune Sciences
ALPN
|
-57.6 M | - | - | $ 2.17 B | ||
|
CymaBay Therapeutics
CBAY
|
-101 M | - | - | $ 3.45 B | ||
|
Aileron Therapeutics
ALRN
|
-50.6 M | - | 10.36 % | $ 9.8 M |